ROIV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Roivant Sciences Ltd (ROIV) is not a strong buy at the moment for a beginner investor with a long-term horizon. While the stock has positive analyst sentiment and potential upside based on price targets, the company's recent financial performance is significantly weak, and technical indicators do not suggest a strong entry point. Additionally, there are no recent news catalysts or proprietary trading signals to support immediate action. A hold strategy is recommended until further clarity on financial recovery or stronger technical signals emerge.
The MACD histogram is negative (-0.348) and contracting, indicating bearish momentum. RSI is neutral at 38.459, and moving averages are converging, showing no clear trend. Key support is at 26.847, and resistance is at 28.863. The stock is trading near its pivot level of 27.855, suggesting indecision in price action.
Analyst price targets have been raised recently, with targets ranging from $29 to $35, indicating potential upside. The settlement with Moderna has resolved a major overhang, shifting focus to clinical readouts. Positive Phase 2 data for brepocitinib in cutaneous sarcoidosis adds potential value.
The company's financial performance in Q3 2026 is significantly weak, with revenue down -77.83% YoY, net income down -256.98% YoY, and EPS down -265.22% YoY. Gross margin also dropped by -33.10%. No recent news or influential trading activity to act as a catalyst. Technical indicators suggest no strong momentum.
In Q3 2026, revenue dropped to $1.999 million (-77.83% YoY), net income fell to -$265.891 million (-256.98% YoY), and EPS declined to -$0.38 (-265.22% YoY). Gross margin decreased to 64.98% (-33.10% YoY). The financials indicate significant deterioration in performance.
Analysts are positive on the stock, with multiple firms raising price targets recently. Bernstein initiated coverage with an Outperform rating and a $35 price target, citing upcoming clinical readouts. JPMorgan and H.C. Wainwright also raised targets, highlighting the resolution of the Moderna settlement as a positive development. However, some risks remain, including potential competition and soft product launches.
